PO.TB09.02 · 肿瘤生物学
单细胞多组学揭示IDH突变型胶质瘤中协调的表观遗传和转录组演化
Single-cell multi-omics uncovers coordinated epigenetic and transcriptomic evolution in IDH-mutant glioma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
IDH突变型胶质瘤(IDH-G)在诊断时通常表现为低级别、生长缓慢的肿瘤,但尽管接受最大化治疗,仍不可避免地进展为高级别和无法治愈的肿瘤。虽然此前的批量测序研究表明IDH突变型胶质瘤在肿瘤进展过程中经历DNA甲基化和转录程序的独特变化,但这些变化如何在细胞水平上共同促进IDH-G演化仍知之甚少。为解决这一问题,我们通过多组学单核测序对一个IDH-G纵向队列(来自19例患者的36份样本)进行分析,从同一单核中共同捕获全长转录(通过Smart-Seq2)和DNA甲基化(通过扩展表征亚硫酸氢盐测序(XRBS))。与我们此前多组学单细胞研究(Chaligne等,Nature Genetics,2021)中用于单细胞DNA甲基化分析的简化表征亚硫酸氢盐测序(RRBS)相比,本研究采用的XRBS提供了更高的CpG岛覆盖度(平均378,888对198,345,P=2.2×10⁻¹⁶),尤其是在非启动子区域。单核RNA测序分析显示,复发后干细胞样状态的比例呈纵向增加,而分化状态的比例相应减少。单核DNA甲基化分析显示,在两个IDH-G亚组(星形细胞瘤和少突胶质细胞瘤)中,IDH-G进展均与甲基化丢失相关,这标志着临床结局更差的肿瘤。这种甲基化丢失在同一个体肿瘤内的恶性细胞中一致地观察到,并与干细胞样群体比例的增加相关。这提示较低的DNA甲基化并非由于细胞状态构成的改变,而是可能作为其基础。对有和没有甲基化丢失的恶性细胞进行的差异甲基化和差异表达基因分析,识别出PRC2靶点的低甲基化和胶质瘤干细胞基因表达的增加,作为干细胞样状态扩增的潜在机制。利用我们基于DNA甲基化信息构建的高分辨率谱系树、直接测量细胞状态可遗传性和转变动态的定量框架,我们发现甲基化降低重塑细胞转变,使干细胞样状态的可遗传性增加、分化减少。本研究在演化框架内整合单细胞甲基化和转录,展示了DNA甲基化丢失如何驱动IDH-G中干细胞样转录状态和改变的细胞状态动态,为解析人类癌症演化提供了蓝图。
查看英文原文 English abstract
IDH-mutant gliomas (IDH-G) typically present as low-grade slow-growing tumors at diagnosis, but invariably progress to high-grade and incurable tumors despite maximal treatment. While previous bulk sequencing studies have shown that IDH-mutant gliomas undergo unique changes in DNA methylation and transcriptional programs during the tumor progression, how these jointly facilitate IDH-G evolution at cellular level has been poorly understood. To address this question, we profiled a longitudinal cohort of IDH-G (36 samples from 19 patients) by multi-omics single-nucleus sequencing, co-capturing full-length transcriptional (by Smart-Seq2) and DNA methylation (by extended-representation bisulfite sequencing (XRBS)) from the same single-nuclei. Compared to reduced-representation bisulfite sequencing (RRBS) used for single-cell DNA methylation profiling in our prior multi-omic single-cell study (Chaligne, et al, Nature Genetics, 2021), the XRBS adopted in this study provided higher coverage of CpG islands (mean of 378,888 vs 198,345, P = 2.2 x 10 -16 ), especially in non-promoter regions. Single-nucleus RNA-sequencing analysis showed a longitudinal increase in the fraction of stem-like state and a reciprocal decrease in that of differentiated state after recurrence. Single-nucleus DNA methylation analysis revealed that in both IDH-G subsets (astrocytoma and oligodendroglioma), IDH-G progression was associated with methylation loss, which marks tumors with worse clinical outcome. This methylation loss was uniformly observed across malignant cells within the same individual tumors and was correlated with the increase in the fraction of stem-like population. This suggests that lower DNA methylation is not due to a change in cell state composition, but rather that it may underlie. Differentially methylated and expressed gene analyses of malignant cells with versus without methylation loss identified hypomethylation of PRC2 targets and increased expression of glioma stem-cell genes as potential mechanisms underlying the expansion of stem-like states. Leveraging our quantitative framework that directly measure cell state heritability and transition dynamics based on high-resolution lineage trees build by DNA methylation information suggested that decreased methylation reshapes cellular transitions to increased heritability of stem-like states and decreased differentiation. This study integrating single-cell methylation and transcription within an evolutionary framework shows how DNA methylation loss drives stem-like transcriptional states and altered cell-state dynamics in IDH-G, offering a blueprint for dissecting evolution in human cancers.
利益披露 Disclosure
M. Nomura, None..
R. Raviram, None..
J. S. Schiffman, None..
L. Bussema, None..
V. Lu, None..
N. Wheeler, None..
J. Lee, None..
Y. Fan, None..
M. H. Zheng, None..
F. Ruiz, None..
H. Danish, None..
S. Kellett, None..
L. Nusrat, None..
R. Chaligne, None..
J. T. Huse, None..
W. Yung, None..
S. Tanaka, None..
N. Saito, None..
S. Das, None..
C. Potenski, None.
D. Landau,
Abbvie consultant.
AstraZeneca consultant.
Illumina ), consultant.
Mission Bio Scientific Advisory Board.
Pangea Scientific Advisory Board.
Alethiomics Scientific Advisory Board.
Montage Bio Scientific Advisory Board.
Veracyte Scientific Advisory Board.
BMS ).
10x Genomics ).
Ultima Genomics ).
M. L. Suva,
Immunitas Therapeutics equity holders, scientific co-founder and advisory board member.